Literature DB >> 6851197

Corticosteroid myopathy: a clinical and pathological study.

A A Khaleeli, R H Edwards, K Gohil, G McPhail, M J Rennie, J Round, E J Ross.   

Abstract

In six patients with Cushing's syndrome and three with steroid myopathy, the clinical, functional, biochemical and structural characteristics of myopathy are described. Proximal muscle weakness occurred in all the patients, preferentially affected the lower limbs and was accompanied by muscle wasting in all but one patient. Force measurements confirmed quadriceps weakness in every patient. Vastus lateralis muscle biopsies showed light microscopic abnormalities in two of three patients with steroid myopathy and one of five patients with Cushing's syndrome. Type II fibre atrophy was the commonest abnormality. Reduced type II mean fibre areas occurred in all the patients with steroid myopathy and were common in Cushing's syndrome patients. Type I mean fibre areas were also reduced in two of the former group and one of the latter group and two further patients in this group had areas at the lower end of the normal range. Abnormalities in electron microscopy, mitochondrial function tests and chemical content of skeletal muscle were frequent and are described and discussed. A plasma creatine kinase activity (CK) at the lower end of the normal range, a myopathic electromyogram (EMG) and a raised 24-h urinary 3-methylhistidine/creatinine ratio on a creatine free diet were other characteristic findings in both groups of patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6851197     DOI: 10.1111/j.1365-2265.1983.tb03198.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  29 in total

Review 1.  Adverse neurologic effects of glucocorticosteroids.

Authors:  D Lacomis; M A Samuels
Journal:  J Gen Intern Med       Date:  1991 Jul-Aug       Impact factor: 5.128

Review 2.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 3.  Exercise following heart transplantation.

Authors:  R W Braith; D G Edwards
Journal:  Sports Med       Date:  2000-09       Impact factor: 11.136

4.  Alpha and beta glucocorticoid receptor mRNA expression in skeletal muscle.

Authors:  S H Korn; E Koerts-de Lang; G E Engel; J W Arends; E F Wouters; F B Thunnissen
Journal:  J Muscle Res Cell Motil       Date:  1998-10       Impact factor: 2.698

Review 5.  Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 6.  Steroid myopathy: some unresolved issues.

Authors:  M A Minetto; F Lanfranco; G Motta; S Allasia; E Arvat; G D'Antona
Journal:  J Endocrinol Invest       Date:  2011-05       Impact factor: 4.256

Review 7.  Diagnostic work-up in steroid myopathy.

Authors:  Marco Alessandro Minetto; Valentina D'Angelo; Emanuela Arvat; Santosh Kesari
Journal:  Endocrine       Date:  2017-11-15       Impact factor: 3.633

8.  Impact of physical training on the ultrastructure of midthigh muscle in normal subjects and in patients treated with glucocorticoids.

Authors:  F F Horber; H Hoopeler; J R Scheidegger; B E Grünig; H Howald; F J Frey
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

9.  Tissue-Engineered Human Myobundle System as a Platform for Evaluation of Skeletal Muscle Injury Biomarkers.

Authors:  Alastair Khodabukus; Amulya Kaza; Jason Wang; Neel Prabhu; Richard Goldstein; Vishal S Vaidya; Nenad Bursac
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

10.  Evaluation of laryngeal findings in users of inhaled steroids.

Authors:  Gul Ozbilen Acar; Nurten Uzun Adatepe; Asim Kaytaz; Deniz Tuna Edizer; Bilun Gemicioglu; Cengiz Yagiz; Ahmet Dirican
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-11-12       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.